The bill adds a new Title XXII to the Social Security Act to establish a federally administered public health plan called the 'Medicare Exchange health plan' to be offered through the ACA exchanges (including the SBHO) in the individual and small‑group markets nationwide beginning plan year 2028. The Secretary of HHS must set geographically varying premiums that cover full actuarial costs, may use innovative payment models, and will generally reimburse providers at rates determined for equivalent items and services under original Medicare.
The package pairs the public option with several market supports and policy shifts: two one‑time $1 billion Treasury funds for start‑up and data modernization; a nationwide reinsurance pool with up to $10 billion authorized per year for the early years; expansion of premium tax credits (removing the 400% cap and addressing the family glitch); and restored authority for HHS to negotiate Medicare prescription drug prices. The bill also conditions Medicare and Medicaid enrollment on participation in the public plan (subject to an opt‑out process) and authorizes antitrust funding and grants to encourage delivery system reforms and integration with social services.
At a Glance
What It Does
Creates a federally run public option (the Medicare Exchange health plan) offered through ACA exchanges in every rating area for the individual and small‑group markets starting plan year 2028, with premiums set by HHS to cover full actuarial costs. It requires plan compliance with ACA qualified‑plan rules, generally ties provider payments to original Medicare rates, authorizes innovative payment pilots, and funds start‑up and data work.
Who It Affects
People eligible for exchange subsidies who are not Medicare beneficiaries, small employers using the Small Business Health Options Program, health care providers who participate in Medicare or Medicaid (who must also participate in the public plan unless they pursue a narrow opt‑out), commercial insurers competing in the exchanges, and drug manufacturers facing restored negotiation authority.
Why It Matters
This is a comprehensive public‑option design that influences prices, provider participation, and the subsidy structure across ACA markets rather than creating a limited state pilot. It directly alters reimbursement norms by anchoring payments to Medicare rates and changes federal subsidy law, so payers, providers, and state regulators will face new operational, contracting, and competitive pressures.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Medicare‑X Choice Act creates a new federal insurance product — the Medicare Exchange health plan — designed to sit inside the ACA marketplaces alongside private plans. HHS must finalize rules quickly, set premiums that fully cover expected costs, and offer at least silver and gold versions; it may offer limited additional plan versions.
The plan is available to exchange‑eligible individuals who are not enrolled in Medicare, and it must meet ACA rules for qualified health plans.
To jump‑start the program the bill appropriates two dedicated funds: a Plan Reserve Fund for establishing and administering the plan, and a Data and Technology Fund for premium modeling and data collection. HHS will collect state and other data (subject to privacy rules) to set geographically sensitive premiums and to measure disparities.
For the initial premium year HHS will use 2027 market rates as a point of reference.On payments, the bill directs HHS to set reimbursement for services delivered to plan enrollees generally at the same rates used by original Medicare (parts A and B), with an explicit allowance to increase those rates by up to 50% in rural areas. HHS also gets authority to negotiate prescription drug prices for the program.
The bill encourages and authorizes a broad menu of alternative payment and delivery models, requires patient‑centered evaluation, and funds grants to support accountable communities for health and social‑service integration.To limit premium volatility and blunt high‑cost cases, the bill requires state‑level single risk pools for plan enrollees (with limited exceptions) and directs HHS to create a nationwide reinsurance mechanism for the highest‑cost individuals, with multi‑year appropriations targeted to early implementation. Finally, the bill amends the tax code to expand premium tax credit eligibility and fixes the family‑coverage affordability 'glitch,' changing subsidy calculations and imposing a small recapture cap for very high‑income households.
The Five Things You Need to Know
Availability: The Medicare Exchange health plan must be offered through the ACA exchanges in all rating areas for both the individual market and the small‑group market beginning plan year 2028.
Funding: The bill creates a Plan Reserve Fund and a Data and Technology Fund and appropriates $1 billion to each for fiscal year 2027 (available until expended) to stand up the program and update actuarial and IT systems.
Provider payment rule: HHS must generally reimburse providers for services to plan enrollees at rates determined for equivalent items and services under original Medicare (parts A and B), while allowing up to a 50% increase for rural areas and permitting innovative payment models.
Reinsurance: HHS must establish a nationwide reinsurance pool to spread the costs of the highest‑cost individual enrollees; Congress authorizes $10 billion per year for fiscal years 2028–2030 to finance that mechanism.
Subsidies and drug pricing: The bill removes the 400% income cap on premium tax credit eligibility, fixes the family‑coverage 'glitch' by tying affordability to the employee’s household income at a 9.5% threshold, adds a $5,000 recapture cap for very high incomes, and restores HHS’s authority to negotiate Medicare prescription drug prices.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishes the Medicare Exchange health plan and start‑up funds
Creates Title XXII and requires HHS to establish a coordinated, low‑cost public health plan branded the 'Medicare Exchange health plan.' The Secretary must make the plan available in the individual and small‑group markets nationwide beginning plan year 2028. The section also sets up two dedicated Treasury funds — a Plan Reserve Fund and a Data and Technology Fund — each receiving a $1 billion appropriation for FY2027 to finance establishment and actuarial/data work.
Eligibility and distribution through exchanges
Limits eligibility to exchange‑eligible individuals who are not enrolled in Medicare, and requires the plan to be offered through the existing federal and state ACA exchanges (including the SBHO). Practically, this means HHS must integrate enrollment, billing, and subsidy flows with existing exchange infrastructure and certify the plan as a qualified health plan under existing exchange rules.
Benefit standards and cost‑sharing
Mandates that the public plan comply with ACA qualified‑plan requirements and offer at least silver and gold metal levels; HHS may offer a limited number of plan versions across other metal levels. Importantly, the plan must cover primary care without any cost‑sharing, an explicit benefit that will shape actuarial value and utilization patterns.
Premium setting and state risk pools
Directs the Secretary to set premiums that cover the full actuarial cost of benefits and administration and to vary those premiums by geography and market (individual vs. small group). For plan year 2028 HHS must set rates by rating area using 2027 market rates as a reference. After 2028, enrollees within a State will belong to a single risk pool unless the State has a particular ACA waiver in place — an arrangement meant to centralize risk within states and limit adverse selection challenges.
Reimbursement and drug pricing authority
Establishes that provider reimbursement for plan enrollees will be determined using the payment rates in original Medicare for equivalent services, with explicit allowances for higher payments in rural areas and for services not covered in original Medicare. The Secretary is also authorized to negotiate prescription drug payment rates for the plan, and to use value‑based and other innovative payment methods.
Provider participation and opt‑out process
Requires health care providers to participate in the public plan to be enrolled in Medicare or to participate in Medicaid, subject to an opt‑out pathway for 'exceptional circumstances' where participation would threaten a provider’s ability to operate. HHS must also create a process for other providers to become participating providers, so network formation and credentialing are centralized under the federal plan.
Delivery system reforms, grants, and social‑service integration
Gives HHS broad authority to experiment with alternative payment models (ACOs, patient‑centered medical homes, partial capitation, telehealth, etc.) and to prioritize reforms that improve outcomes or reduce disparities. It authorizes grants to fund accountable communities for health (eligible recipients include higher‑ed institutions, nonprofits, health agencies), and mandates patient feedback and person‑reported experience metrics in design and evaluation.
Program enforcement and nationwide reinsurance
Amends existing Social Security Act sanction provisions to prohibit providers from imposing coverage restrictions that treat public plan enrollees differently, unless applied uniformly — a tool to prevent de‑facto exclusions. Separately, Section 4 directs HHS to pool highest‑cost individual coverage nationwide and authorizes $10 billion per year for FY2028–2030 to subsidize catastrophic costs and lower premiums for the broader individual market.
Subsidy expansion, Medicare drug‑pricing, and antitrust resources
Makes comprehensive changes to premium tax credit law: removes the 400% income cap, establishes new sliding applicable percentages across income tiers, fixes the family‑coverage affordability 'glitch' by linking affordability to the employee’s household income, and caps recapture for very high incomes. It also removes a restriction in current statute to restore negotiation authority for Medicare prescription drugs, and authorizes funding to DOJ and FTC for antitrust work in health care markets.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Exchange enrollees with lower and moderate incomes — They gain access to a federally administered public plan available in all rating areas and expanded premium tax credits (removes the 400% cap and fixes the family‑coverage affordability test), which together lower net premiums and out‑of‑pocket exposure.
- Rural and underserved patients — The bill explicitly allows higher reimbursement adjustments in rural areas and prioritizes telehealth and delivery reforms, which could expand access to specialty care in underserved regions.
- Community health and social‑service partnerships — The grant program and explicit authorization to integrate health care with housing, food, and transportation support organizations will channel funding and technical assistance to entities that coordinate nonmedical supports.
- Small businesses and employees in the small‑group market — The public plan's availability through the SBHO creates an additional option intended to reduce premiums and offer a standardized product across rating areas.
Who Bears the Cost
- Commercial insurers operating on the exchanges — They face a new, competitively priced federal plan that anchors premiums and reimbursement to Medicare rates and may erode market share or require plan redesigns.
- Some providers and health systems — Payment anchoring to Medicare rates (even with allowances) and greater uptake of value‑based models could reduce revenue for providers whose negotiated commercial rates exceed Medicare; administrative costs for new credentialing and data reporting also rise.
- Drug manufacturers — Restored HHS authority to negotiate drug prices for the plan (and the removal of prior statutory limits) increases pressure on list prices and contracting strategies.
- Federal and HHS program budgets in the near term — Start‑up appropriations, reinsurance funding, and increased administrative responsibilities impose upfront federal costs and require sustained data and actuarial investments.
Key Issues
The Core Tension
The central dilemma is straightforward: the bill seeks to expand affordable, standardized coverage by anchoring a public option to Medicare prices and federal subsidies, which can lower premiums for enrollees but risks straining provider revenues, disrupting existing insurance markets, and requiring large federal investments in data, payment reform, and market oversight—tradeoffs that lack a one‑size‑fits‑all solution.
The bill's mechanics create several practical tensions. First, anchoring reimbursement to Medicare rates aims to lower costs but risks provider pushback and potential network narrowing if commercial volume shrinks; the opt‑out carve‑out for 'exceptional circumstances' is vague and could trigger litigation or inconsistent application across regions.
Second, premium‑setting authority rests with HHS and depends on new data systems and actuarial modeling funded by a one‑time Data and Technology Fund; insufficient data or underpricing in early years could leave the plan either uncompetitive or financially unsustainable. Third, the nationwide reinsurance pool and state single risk pools try to manage adverse selection and geographic variation, but they create coordination challenges with state regulators and existing ACA solvency protections.
Implementation also hinges on political and legal risk: restoring negotiation authority for Medicare drug prices removes a statutory constraint but may prompt industry litigation or aggressive manufacturer responses (e.g., formulary changes). Meanwhile, the requirement that Medicare and Medicaid providers also participate in the public option (subject to opt‑out) is a blunt instrument to build networks quickly but could disrupt provider contracting and cross‑subsidization strategies.
Finally, many of the bill’s design levers — the level of provider payment increases in rural areas, the scope of services added after the mandated study, and the shape of alternative payment models — are delegated to HHS rulemaking, leaving significant policy detail undecided at enactment.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.